Research Articles
GLP-1 Receptor Agonism Explained: Molecular Mechanism Deep Dive
Deep dive on GLP-1 receptor agonism — binding affinities, signaling cascades, GIP/GLP-1 dual agonism, and triple-agonist research from 2024–2026 literature.
Read article →ArticleSURMOUNT-1 Trial Deep Dive: Tirzepatide Phase 3 | Artemis Labs
Detailed analysis of the SURMOUNT-1 phase 3 tirzepatide trial — 72-week efficacy data, ~20.9% mean weight reduction, safety profile, and 2026 research implications.
Read article →ArticleWeight Loss Research Peptides 2026 | Artemis Labs
Pillar guide to weight loss research peptides — tirzepatide, retatrutide, cagrilintide, AOD-9604, 5-Amino-1MQ — with 2024-2026 trial data and comparative mechanisms.
Read article →ArticleTirzepatide vs Retatrutide: Mechanism & Efficacy 2026 | Artemis Labs
Side-by-side comparison of tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple) — efficacy, mechanism, safety, and research selection criteria.
Read article →ArticleTRIUMPH-4 Retatrutide Trial Design 2026 | Artemis Labs
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at…
Read article →